8-K: ADC Therapeutics Reports Q3 2025 Results, ZYNLONTA Progress

ADC Therapeutics announced its third quarter 2025 financial results, highlighting progress in its ZYNLONTA clinical trials and a strengthened balance sheet from a recent $60 million PIPE financing.

Summary

• Net product revenues for the third quarter ended September 30, 2025, were $15.8 million, a decrease from $18.0 million for the same period in 2024, primarily due to lower sales volume.
• The net loss for Q3 2025 was $41.0 million, or $0.30 per basic and diluted share, an improvement compared to a net loss of $44.0 million, or $0.42 per share, in Q3 2024.
• Adjusted net loss (non-GAAP) for Q3 2025 was $25.5 million, or $0.19 per share, down from $29.4 million, or $0.28 per share, in Q3 2024.
• Year-to-date net loss for the nine months ended September 30, 2025, increased to $136.2 million from $127.1 million in 2024, driven by increased R&D expense, restructuring costs, and lower interest income.
• The company completed a $60 million private investment in public equity (PIPE) financing in October 2025, yielding net proceeds of approximately $57.6 million.
• Cash and cash equivalents stood at $234.7 million as of September 30, 2025, which would increase to an estimated $292.3 million after giving effect to the net proceeds from the PIPE financing.
• Updated data from the LOTIS-7 Phase 1b trial, evaluating ZYNLONTA in combination with glofitamab for relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), is expected by the end of 2025.
• Topline results from the LOTIS-5 Phase 3 confirmatory trial of ZYNLONTA in combination with rituximab in patients with 2L+ DLBCL are anticipated in the first half of 2026.
• Updated data from a Phase 2 investigator-initiated trial (IIT) of ZYNLONTA plus rituximab in r/r follicular lymphoma (FL) showed an overall response rate (ORR) of 98.2% and a complete response rate (CR) of 83.6% in 55 efficacy evaluable patients, with median progression-free survival (PFS) not reached after a median follow-up of 28 months.
• IND-enabling activities for the company's exatecan-based, prostate-specific membrane antigen (PSMA)-targeting ADC are ongoing and expected to be completed by the end of 2025.
• Research and Development (R&D) expense decreased to $26.8 million in Q3 2025 from $32.5 million in Q3 2024, mainly due to reduced spending on discontinued programs.
• General & Administrative (G&A) expense decreased to $8.3 million in Q3 2025 from $10.0 million in Q3 2024, primarily due to lower external professional fees.
• The company incurred $0.4 million in restructuring, impairment, and other related costs in Q3 2025, and $13.5 million year-to-date 2025, associated with a strategic reprioritization and restructuring plan announced in June 2025.

Sentiment

Score: 7

Explanation: The filing presents a generally positive outlook, driven by improved Q3 net loss, successful capital raise extending cash runway, and encouraging clinical data for ZYNLONTA in follicular lymphoma. While product revenues saw a slight decline, the strategic focus and pipeline progress, especially with upcoming catalysts, contribute to a favorable sentiment. The year-to-date net loss increase and restructuring costs are noted but are offset by the positive operational and financial strengthening.

Positives

• Net loss for Q3 2025 decreased to $41.0 million from $44.0 million in Q3 2024, and adjusted net loss also decreased to $25.5 million from $29.4 million.
• The successful completion of a $60 million PIPE financing, providing approximately $57.6 million in net proceeds, significantly strengthens the balance sheet and extends the cash runway into 2028.
• Encouraging updated data from the Phase 2 IIT of ZYNLONTA plus rituximab in r/r follicular lymphoma, demonstrating a 98.2% ORR and 83.6% CR, with median PFS not reached after 28 months.
• Reduced R&D, Selling and Marketing, and General & Administrative expenses in Q3 2025 compared to Q3 2024, reflecting cost management and strategic reprioritization.
• Advancing IND-enabling activities for a PSMA-targeting ADC, with completion expected by year-end 2025, indicating pipeline progression.

Negatives

• Net product revenues decreased to $15.8 million in Q3 2025 from $18.0 million in Q3 2024, primarily driven by lower sales volume.
• Year-to-date net loss for the nine months ended September 30, 2025, increased to $136.2 million from $127.1 million in 2024.
• Incurred $13.5 million in restructuring, impairment, and other related costs year-to-date 2025, including $6.2 million in employee severance and $6.4 million in non-cash asset impairment, indicating significant one-time costs associated with strategic changes.

Risks

• The success of the company's strategic restructuring plan is subject to various factors and may not achieve the desired outcomes.
• Changes in estimated costs associated with the restructuring plan, including workforce reduction and planned closure of the UK facility, could impact financial results.
• Future LOTIS-7 clinical trial results may not be consistent with or different from the data previously presented at EHA and ICML, affecting future compendia and regulatory strategy.
• Uncertainty exists regarding the timing of the progression-free survival (PFS) events and topline data release for LOTIS-5, as well as the trial's results and the potential for full FDA approval.
• The company's ability to grow ZYNLONTA revenue in the United States and achieve potential peak revenue is not guaranteed.
• The ability of partners to commercialize ZYNLONTA in foreign markets and obtain regulatory approval in foreign jurisdictions is a risk.
• The timing and results of the company's or its partners' research and development projects or clinical trials, including LOTIS 5 and 7, as well as early pre-clinical research for the exatecan-based ADC targeting PSMA, are uncertain.
• The timing and results of investigator-initiated trials, including those studying FL and MZL, and their potential regulatory and/or compendia strategy and future opportunity, are not assured.
• The timing and outcome of regulatory submissions for the company's products or product candidates are subject to regulatory review and approval processes.
• Actions by the FDA or foreign regulatory authorities could impact product development, approval, or commercialization.
• The company's indebtedness, including facilities with Healthcare Royalty Management, Blue Owl, and Oaktree, imposes restrictions on its activities and requires significant cash to service.
• The company's ability to comply with the terms of its various loan agreements and repay such indebtedness is a financial risk.
• The ability to obtain sufficient financial and other resources for its research, development, clinical, and commercial activities is crucial for continued operations.
• Uncertainties of international trade policies, including tariffs, sanctions, and trade barriers, could potentially impact the business, financial condition, and results of operations.

Future Outlook

The company anticipates multiple clinical catalysts, including updated LOTIS-7 data by year-end 2025 and LOTIS-5 topline data in the first half of 2026. They plan to engage with the FDA for LOTIS-7 and submit a supplemental Biologics License Application for LOTIS-5 assuming positive results. IND-enabling activities for a PSMA-targeting ADC are expected to conclude by year-end 2025, and the recent PIPE financing is expected to fund ZYNLONTA expansion and extend the cash runway into 2028.

Management Comments

• "The successful completion of our most recent PIPE financing strengthens our balance sheet and provides the resources to further invest in ZYNLONTA as we anticipate advancing into earlier lines of therapy for DLBCL and into indolent lymphomas." Ameet Mallik, Chief Executive Officer.
• "We look forward to multiple upcoming clinical catalysts expected across LOTIS-7, LOTIS-5, and the ongoing Phase 2 IITs, starting with LOTIS-7 before the end of this year and continuing with data readouts throughout 2026." Ameet Mallik, Chief Executive Officer.

Industry Context

ADC Therapeutics operates in the highly competitive and innovation-driven biotechnology and pharmaceutical industry, specifically focusing on antibody-drug conjugates (ADCs) for oncology. The progress with ZYNLONTA in DLBCL and follicular lymphoma, alongside the development of a PSMA-targeting ADC, positions the company within the growing market for targeted cancer therapies. The successful PIPE financing reflects continued investor interest in the ADC space and the potential for ZYNLONTA to expand into earlier lines of therapy and new indications, aligning with the industry trend towards combination therapies and broader market penetration for approved drugs.

Comparison to Industry Standards

• ZYNLONTA (loncastuximab tesirine-lpyl) is a CD19-directed ADC, positioning it in competition with other CD19-targeting therapies and ADCs used in relapsed/refractory DLBCL and potentially follicular lymphoma, such as CAR-T cell therapies (e.g., Yescarta, Kymriah) and bispecific antibodies (e.g., glofitamab, epcoritamab).
• The reported 98.2% overall response rate and 83.6% complete response rate for ZYNLONTA plus rituximab in r/r follicular lymphoma are strong results, potentially indicating a highly effective regimen that could compare favorably to existing or emerging combination therapies in this patient population.
• The development of a PSMA-targeting ADC places the company in the competitive landscape for prostate cancer treatments, including other ADCs or radioligand therapies targeting PSMA (e.g., Pluvicto).
• The strengthened cash position, with an expected runway into 2028 following the PIPE financing, provides a relatively stable financial outlook for a clinical-stage biotechnology company, which is a key indicator of operational viability and ability to fund ongoing R&D and commercialization efforts, often a challenge for smaller biotechs.

Stakeholder Impact

• Shareholders: The PIPE financing, while dilutive, strengthens the balance sheet and extends the cash runway, potentially increasing long-term value. Positive clinical trial updates could further influence share price.
• Employees: The company incurred $6.2 million in employee severance and related benefit costs as part of a strategic reprioritization and restructuring plan announced in June 2025, indicating workforce reductions.
• Customers (Patients): Continued clinical development of ZYNLONTA in new indications and earlier lines of therapy, and the PSMA-targeting ADC, offers potential new treatment options for patients with lymphoma and prostate cancer.
• Creditors: The strengthened balance sheet from the PIPE financing improves the company's ability to service its indebtedness, including facilities with Healthcare Royalty Management, Blue Owl, and Oaktree.
• Suppliers: A more stable financial position generally benefits supplier relationships, though no direct impact was mentioned.

Next Steps

• Share additional data from the LOTIS-7 trial through a corporate update by the end of 2025.
• Engage with the U.S. Food and Drug Administration (FDA) once sufficient data with longer follow-up is available for LOTIS-7.
• Provide topline data in the first half of 2026 from the LOTIS-5 Phase 3 confirmatory trial.
• Submit a supplemental Biologics License Application (sBLA) to regulatory authorities for LOTIS-5, assuming positive results.
• Pursue publication and compendia inclusion for LOTIS-7 and LOTIS-5 in the first half of 2027.
• Assess regulatory and updated compendia pathways for ZYNLONTA in r/r follicular lymphoma as soon as sufficient data are available.
• Complete IND-enabling activities for the PSMA-targeting ADC by the end of 2025.
• Host a conference call and live audio webcast on November 10, 2025, to discuss Q3 2025 financial results and provide a company update.

Key Dates

Recommendation

While ADC Therapeutics reported a decline in Q3 product revenues, the company demonstrated improved net loss and successfully completed a $60 million PIPE financing, significantly strengthening its cash position and extending its runway into 2028. The clinical data for ZYNLONTA in r/r follicular lymphoma is highly encouraging, and upcoming catalysts for LOTIS-7 and LOTIS-5 are critical. However, the year-to-date increase in net loss and the ongoing need to grow ZYNLONTA revenue warrant a cautious approach. Investors should hold, awaiting the outcomes of the pivotal LOTIS-5 trial and further revenue growth before making a more definitive investment decision.

Keywords

ADC Therapeutics, ZYNLONTA, DLBCL, Follicular Lymphoma, Antibody Drug Conjugates, ADCs, Biotechnology, Pharmaceuticals, Oncology, Clinical Trials, PIPE Financing, Financial Results, Q3 2025, PSMA-targeting ADC, Loncastuximab Tesirine